These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25777468)

  • 1. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
    Smith DC; Kalebic T; Infante JR; Siu LL; Sullivan D; Vlahovic G; Kauh JS; Gao F; Berger AJ; Tirrell S; Gupta N; Di Bacco A; Berg D; Liu G; Lin J; Hui AM; Thompson JA
    Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
    Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
    Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
    Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
    Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Hanley MJ; Gupta N; Venkatakrishnan K; Bessudo A; Sharma S; O'Neil BH; Wang B; van de Velde H; Nemunaitis J
    J Clin Pharmacol; 2018 Jan; 58(1):114-121. PubMed ID: 28783865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
    Assouline SE; Chang J; Cheson BD; Rifkin R; Hamburg S; Reyes R; Hui AM; Yu J; Gupta N; Di Bacco A; Shou Y; Martin P
    Blood Cancer J; 2014 Oct; 4(10):e251. PubMed ID: 25325301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
    Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
    Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
    Gupta N; Huh Y; Hutmacher MM; Ottinger S; Hui AM; Venkatakrishnan K
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):507-16. PubMed ID: 26141494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Sanchorawala V; Palladini G; Kukreti V; Zonder JA; Cohen AD; Seldin DC; Dispenzieri A; Jaccard A; Schönland SO; Berg D; Yang H; Gupta N; Hui AM; Comenzo RL; Merlini G
    Blood; 2017 Aug; 130(5):597-605. PubMed ID: 28550039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
    Infante JR; Mendelson DS; Burris HA; Bendell JC; Tolcher AW; Gordon MS; Gillenwater HH; Arastu-Kapur S; Wong HL; Papadopoulos KP
    Invest New Drugs; 2016 Apr; 34(2):216-24. PubMed ID: 26924128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
    Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
    Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
    San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
    Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Gupta N; Hanley MJ; Venkatakrishnan K; Wang B; Sharma S; Bessudo A; Hui AM; Nemunaitis J
    J Clin Pharmacol; 2016 Oct; 56(10):1288-95. PubMed ID: 26872892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixazomib: First Global Approval.
    Shirley M
    Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
    Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
    Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Diderichsen PM; Yang H; Ke A; Teng Z; Labotka R; Berg D; Patel C; Liu G; van de Velde H; Venkatakrishnan K
    Clin Pharmacol Ther; 2019 Feb; 105(2):376-387. PubMed ID: 29446068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.